Arrivo bags $45M Series B to fund major depression late-stage test and PhII-ready pancreatitis asset

Ayisha Sharma

News Reporter

Arrivo BioVentures has closed an oversubscribed $45.25 million Series B fundraise with an eye to progress its pipeline through the next stage of trials, including …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Arrivo bags $45M Series B to fund major depression late-stage test and PhII-ready pancreatitis asset

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

WuXi companies may sell units impacted by Biosecure — report

Biotech's third quarter was relatively bright — with a few caveats

EMA reviews hair loss products following concerns about suicidal thoughts

After $14B exit, Karuna co-founder finds next bet; Ex-Regenxbio CEO Ken Mills heads to Tagworks

Sanofi sells rare disease drug Enjaymo to Recordati for $825M upfront

3 Tiers for AAV Potency Assay Development Success

Ar­ri­vo bags $45M Se­ries B to fund ma­jor de­pres­sion late-stage test and PhII-ready pan­cre­ati­tis as­set

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Arrivo bags $45M Series B to fund major depression late-stage test and PhII-ready pancreatitis asset